United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider

UBC ClinResearch to Expand Global Reach in Pioneering Field

    BETHESDA, Md., Sept. 10 /PRNewswire/ -- United BioSource Corporation
 (UBC) today announced the acquisition of an ownership interest in
 ClinResearch GmbH, a global leader in technology solutions and services for
 flexible, or adaptive, clinical trials. Headquartered in Cologne, Germany,
 with more than 100 employees, ClinResearch has designed and implemented 80
 adaptive programs over the past seven years. ClinResearch's co-founder,
 Reinhard Eisebitt, is a co-developer of the leading software used by
 pharmaceutical companies and contract research organizations (CROs)
 throughout the world to support the rigorous statistical requirements of
 adaptive trials.
     (Logo: http://www.newscom.com/cgi-bin/prnh/20070910/NEM007LOGO )
     ClinResearch, which will now operate under the name UBC ClinResearch,
 will be a centerpiece of UBC's adaptive design clinical trial offering and
 will deliver a full service, global solution for pharmaceutical,
 biotechnology and medical device companies seeking to capitalize on the
 benefits of adaptive design in their clinical development strategy.
     "We are thrilled to welcome ClinResearch to the UBC family," said Ethan
 Leder, CEO of UBC. "Having worked with the founders for several years, we
 know that they are an excellent fit with our culture and vision. They are
 innovative and science driven, and have built a world-class organization
 with a track record of developing and executing technology solutions that
 we plan to introduce aggressively to our growing base of sponsor and CRO
 clients."
     "The interest in adaptive design is accelerating from the early adopter
 to the rapid growth stage. We are excited to be joining an organization
 with the resources to allow us to capitalize on this opportunity," noted
 Michael Fischer, PhD, founder of ClinResearch. Fischer added, "We are
 moving forward with expansion plans to fulfill demand on our global
 projects with UBC and anticipate growth in Cologne, as well as in our
 offices in Russia and the Ukraine to benefit our clients."
     According to Patrick Lindsay, Executive Vice President of UBC,
 "ClinResearch's leadership in adaptive design is consistent with UBC's
 focus on innovative solutions for clinical development. Reinhard Eisebitt,
 ClinResearch's co-founder, is recognized by the FDA and European regulatory
 authorities as a thought leader in adaptive design based on the proprietary
 software and techniques that he helped develop. We look forward to bringing
 our combined strengths in this novel and quickly evolving methodology to
 the industry." The ClinResearch announcement is the latest in a series of
 transactions made since UBC raised $153 million in equity capital from a
 syndicate of leading private equity firms in 2003.
     Since 1999, ClinResearch, GmbH, headquartered in Cologne, Germany, has
 been a leader in planning, conducting and reporting clinical studies for
 the pharmaceutical and medical device industries. For more information,
 visit www.clinresearch.com.
     United BioSource Corporation (UBC) is a global pharmaceutical services
 organization that helps emerging and established life science companies
 develop and commercialize medical products. UBC specializes in offering new
 and innovative ways to study drugs and devices by offering expertise in
 science, strategy and execution.
     UBC is headquartered in Bethesda, Maryland, with offices in the United
 States, Canada, Europe and South America. For more information, visit
 www.unitedbiosource.com or call 866-458-1096.
     CONTACT: Tess Drahzal, +1 (240) 644-0420, info@unitedbiosource.com
 
 

SOURCE United BioSource Corporation